Xu Bin, Li Yan-Li, Xu Ming, Yu Chang-Chun, Lian Meng-Qiao, Tang Ze-Yao, Li Chuan-Xun, Lin Yuan
Department of Pharmacology, Dalian Medical University, Dalian 116044, China.
Acta Pharmacol Sin. 2017 May;38(5):688-698. doi: 10.1038/aps.2016.168. Epub 2017 Mar 6.
Geniposide is an iridoid glycosides purified from the fruit of Gardenia jasminoides Ellis, which is known to have antiinflammatory, anti-oxidative and anti-tumor activities. The present study aimed to investigate the effects of geniposide on experimental rat colitis and to reveal the related mechanisms. Experimental rat colitis was induced by rectal administration of a TNBS solution. The rats were treated with geniposide (25, 50 mg·kg·d, ig) or with sulfasalazine (SASP, 100 mg·kg·d, ig) as positive control for 14 consecutive days. A Caco-2 cell monolayer exposed to lipopolysaccharides (LPS) was used as an epithelial barrier dysfunction model. Transepithelial electrical resistance (TER) was measured to evaluate intestinal barrier function. In rats with TNBS-induced colitis, administration of geniposide or SASP significantly increased the TNBS-decreased body weight and ameliorated TNBS-induced experimental colitis and related symptoms. Geniposide or SASP suppressed inflammatory cytokine (TNF-α, IL-1β, and IL-6) release and neutrophil infiltration (myeloperoxidase activity) in the colon. In Caco-2 cells, geniposide (25-100 μg/mL) ameliorated LPS-induced endothelial barrier dysfunction via dose-dependently increasing transepithelial electrical resistance (TER). The results from both in vivo and in vitro studies revealed that geniposide down-regulated NF-κB, COX-2, iNOS and MLCK protein expression, up-regulated the expression of tight junction proteins (occludin and ZO-1), and facilitated AMPK phosphorylation. Both AMPK siRNA transfection and AMPK overexpression abrogated the geniposide-reduced MLCK protein expression, suggesting that geniposide ameliorated barrier dysfunction via AMPK-mediated inhibition of the MLCK pathway. In conclusion, geniposide ameliorated TNBS-induced experimental rat colitis by both reducing inflammation and modulating the disrupted epithelial barrier function via activating the AMPK signaling pathway.
栀子苷是从栀子果实中纯化得到的一种环烯醚萜苷,已知其具有抗炎、抗氧化和抗肿瘤活性。本研究旨在探讨栀子苷对实验性大鼠结肠炎的影响,并揭示其相关机制。通过直肠给予TNBS溶液诱导实验性大鼠结肠炎。大鼠连续14天接受栀子苷(25、50mg·kg·d,灌胃)或柳氮磺胺吡啶(SASP,100mg·kg·d,灌胃)作为阳性对照治疗。将暴露于脂多糖(LPS)的Caco-2细胞单层用作上皮屏障功能障碍模型。测量跨上皮电阻(TER)以评估肠道屏障功能。在TNBS诱导的结肠炎大鼠中,给予栀子苷或SASP可显著增加TNBS降低的体重,并改善TNBS诱导的实验性结肠炎及相关症状。栀子苷或SASP可抑制结肠中炎性细胞因子(TNF-α、IL-1β和IL-6)的释放以及中性粒细胞浸润(髓过氧化物酶活性)。在Caco-2细胞中,栀子苷(25 - 100μg/mL)通过剂量依赖性增加跨上皮电阻(TER)改善LPS诱导的内皮屏障功能障碍。体内和体外研究结果均表明,栀子苷下调NF-κB、COX-2、iNOS和MLCK蛋白表达,上调紧密连接蛋白(occludin和ZO-1)的表达,并促进AMPK磷酸化。AMPK siRNA转染和AMPK过表达均消除了栀子苷降低的MLCK蛋白表达,表明栀子苷通过AMPK介导的对MLCK途径的抑制改善屏障功能障碍。总之,栀子苷通过减轻炎症和激活AMPK信号通路调节受损的上皮屏障功能,从而改善TNBS诱导的实验性大鼠结肠炎。